As It Targets Multiple Large Market Opportunities, Lexaria Bioscience Corp. (NASDAQ: LEXX) Is Leveraging Elaborate Studies to Progressively Remove Risks Associated with Commercialization, Regulation
- Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
- The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
- Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
- The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation
Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”).
“We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success,” Lexaria CEO Chris Bunka wrote in a January 27 annual update to its stakeholders (https://nnw.fm/gQHZ6).
The company’s multifaceted operational approach leverages its versatile and disruptive DehydraTECH(TM) technology, which is currently protected by a total of 23 granted patents worldwide. Designed specifically for delivering fat-soluble drugs and active pharmaceutical ingredients, DehydraTECH pairs the active ingredients with a fatty acid oil, such as high oleic sunflower oil. It then applies the resultant compound to food or carrier particles such as sorbitol or gum Arabic before a dehydration synthesis procedure is performed. The final step entails rendering the product as powder or liquid (https://nnw.fm/qzBn3).
“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website reads. And multiple studies have supported this statement.
Most recently, Lexaria announced positive results from an animal study, PDE5-A21-1, investigating DehydraTECH processing of PDE5 inhibitor sildenafil for potential application in the management of erectile dysfunction. Conducted at a US-based, third-party independent laboratory, the study involved 20 male Sprague-Dawley rats, half of which were treated with one dose of the DehydraTECH-sildenafil, with the rest receiving generic concentration-matched, control-sildenafil formulation.
The PDE5-A21-1 study showed that DehydraTECH technology delivered 74% more sildenafil into the bloodstream on average than the control just four minutes after dosing. After another three minutes, the DehydraTECH-sildenafil formulation reached an average blood level higher than the control formulation achieved at any point during the study. Further, the DehydraTECH-sildenafil reached a maximum concentration in the bloodstream (“Cmax”) that was approximately 70% higher and at a 25% faster rate than generic sildenafil control formulation.
With the common complaint among many sildenafil users being that it is slow to act, the findings of the PDE5-A21-1 study could usher a new dispensation as regards the development of better and faster-acting sildenafil oral formulations. The results supported further investigation involving a larger number of animals.
Overall, Lexaria aims to leverage positive results from such studies to journey step by step toward removing risks associated with commercialization and regulation. Eventually, the company says, with enough positive data, the formula will tilt in its direction.
“Our R&D focus for 2021 was to investigate DehydraTECH-CBD for possible hypertension and heart disease applications; to further our knowledge of DehydraTECH-nicotine as a replacement for damaging and deadly lung-based absorption methods; and to learn whether DehydraTECH would be compatible with antiviral drugs. We were successful in each of these primary areas of investigation,” Bunka wrote.
Looking ahead to 2022, Lexaria plans to launch three major studies between March and April: the human sublingual/buccal tissue study (oral nicotine), the animal seizure study (“CBD”), and its most ambitious study yet, the 6-week human hypertension study (“CBD”). The goal of these three studies is to generate sufficient data to support either regulated IND-type applications or influence corporate partnerships. At the same time, Lexaria will also be conducting several smaller studies throughout the year and will update shareholders when appropriate.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Leveraging the versatility and benefits of its DehydraTECH(TM) technology, Lexaria is targeting multiple large market opportunities as it attempts to ensure it has multiple paths to success
- The technology aims to help companies offering oral drugs, supplements, and nicotine formulations to improve the effectiveness of their existing or planned products
- Lexaria has undertaken various studies whose findings show the benefits of DehydraTECH-processed products relative to controls
- The company intends to use the positive results from its studies to incrementally remove risks associated with commercialization and regulation
Lexaria Bioscience (NASDAQ: LEXX), a global drug delivery technology company transforming existing consumer products and medication by increasing their bioavailability, speed of onset, and brain absorption, is currently targeting multiple large market opportunities, ranging from cardiovascular drugs, antivirals, human hormones, and phosphodiesterase inhibitor (“PDE5 inhibitor”) formulations to nicotine replacement, and cannabidiol (“CBD”).
“We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $10 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success,” Lexaria CEO Chris Bunka wrote in a January 27 annual update to its stakeholders (https://nnw.fm/gQHZ6).
The company’s multifaceted operational approach leverages its versatile and disruptive DehydraTECH(TM) technology, which is currently protected by a total of 23 granted patents worldwide. Designed specifically for delivering fat-soluble drugs and active pharmaceutical ingredients, DehydraTECH pairs the active ingredients with a fatty acid oil, such as high oleic sunflower oil. It then applies the resultant compound to food or carrier particles such as sorbitol or gum Arabic before a dehydration synthesis procedure is performed. The final step entails rendering the product as powder or liquid (https://nnw.fm/qzBn3).
“Lexaria’s technology is best thought of as an additional layer that companies offering consumer supplements, prescription and non-prescription based drugs, and nicotine products can utilize to improve the effectiveness of their existing or planned new products,” the company’s website reads. And multiple studies have supported this statement.
Most recently, Lexaria announced positive results from an animal study, PDE5-A21-1, investigating DehydraTECH processing of PDE5 inhibitor sildenafil for potential application in the management of erectile dysfunction. Conducted at a US-based, third-party independent laboratory, the study involved 20 male Sprague-Dawley rats, half of which were treated with one dose of the DehydraTECH-sildenafil, with the rest receiving generic concentration-matched, control-sildenafil formulation.
The PDE5-A21-1 study showed that DehydraTECH technology delivered 74% more sildenafil into the bloodstream on average than the control just four minutes after dosing. After another three minutes, the DehydraTECH-sildenafil formulation reached an average blood level higher than the control formulation achieved at any point during the study. Further, the DehydraTECH-sildenafil reached a maximum concentration in the bloodstream (“Cmax”) that was approximately 70% higher and at a 25% faster rate than generic sildenafil control formulation.
With the common complaint among many sildenafil users being that it is slow to act, the findings of the PDE5-A21-1 study could usher a new dispensation as regards the development of better and faster-acting sildenafil oral formulations. The results supported further investigation involving a larger number of animals.
Overall, Lexaria aims to leverage positive results from such studies to journey step by step toward removing risks associated with commercialization and regulation. Eventually, the company says, with enough positive data, the formula will tilt in its direction.
“Our R&D focus for 2021 was to investigate DehydraTECH-CBD for possible hypertension and heart disease applications; to further our knowledge of DehydraTECH-nicotine as a replacement for damaging and deadly lung-based absorption methods; and to learn whether DehydraTECH would be compatible with antiviral drugs. We were successful in each of these primary areas of investigation,” Bunka wrote.
Looking ahead to 2022, Lexaria plans to launch three major studies between March and April: the human sublingual/buccal tissue study (oral nicotine), the animal seizure study (“CBD”), and its most ambitious study yet, the 6-week human hypertension study (“CBD”). The goal of these three studies is to generate sufficient data to support either regulated IND-type applications or influence corporate partnerships. At the same time, Lexaria will also be conducting several smaller studies throughout the year and will update shareholders when appropriate.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
